What Is FGF17? Definition and What Research Reports

Definition

FGF17 (fibroblast growth factor 17) is a secreted signalling protein encoded by the FGF17 gene in humans and the Fgf17 gene in mice. It belongs to the fibroblast growth factor (FGF) family and, within it, to the FGF8 subfamily, whose members are best known for organising tissue boundaries during embryonic development. In the published literature the term "FGF17" is used in several distinct senses: as a gene screened in reproductive endocrinology cohorts, as an endogenous protein measured in tissue or fluid, as a recombinant reagent added to cultured cells, and as a candidate factor infused into animals in aging research. Because these usages are not interchangeable, reading any FGF17 claim alongside its model system matters.

What Class of Molecule Is FGF17?

FGF17 is a protein growth factor, not a short synthetic peptide of the kind often discussed under the umbrella term "research peptides." Fibroblast growth factors are secreted polypeptides that act on cell-surface fibroblast growth factor receptors, and FGF17 is grouped with FGF8 and FGF18 on the basis of sequence and functional similarity. That grouping explains why FGF8 and FGF17 are so often examined in the same experiments: a 2000 mouse developmental study described temporal and spatial gradients of Fgf8 and Fgf17 regulating proliferation and differentiation of midline cerebellar structures (PMID 10751172).

Where It Comes From

Endogenously, FGF17 is produced by cells rather than administered. A 2024 review summarised Fgf17 as a regulator of the mid/hindbrain boundary in mammals, the signalling region that helps set up midbrain and cerebellar territory during development (PMID 39327214). Expression is not confined to the nervous system: a 2004 study reported that FGF17 acts as an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia (PMID 15129425).

In laboratories, FGF17 is typically handled as a recombinant protein produced in bacterial or mammalian expression systems and supplied as a research chemical or cell-culture reagent. Recombinant growth factors of this type are generally labelled for research use only and are not approved medicines.

How the Term Is Used in Peptide and Protein Research

• Developmental neuroscience: as a patterning signal at the midbrain–hindbrain boundary and in cerebellar development.
• Reproductive genetics: as one gene in panels screened in congenital or idiopathic hypogonadotropic hypogonadism.
• Stem-cell methodology: as a recombinant factor added to differentiation protocols to bias cell identity.
• Aging biology: as a candidate mediator identified in cerebrospinal fluid (CSF) transfer experiments in mice.
• Oncology and tissue biology: as a measured transcript or protein in tumour and hyperplastic tissue datasets.

What the Published Literature Reports

Brain Patterning and Cerebellar Development

The oldest strand of FGF17 research is developmental. The 2000 mouse study reported that graded Fgf8 and Fgf17 signalling influenced proliferation and differentiation of midline cerebellar structures, placing the two factors in an overlapping but non-identical role (PMID 10751172). The 2024 review consolidated subsequent work and described Fgf17 as a regulator of the mid/hindbrain boundary in mammals (PMID 39327214).

Behaviour in Fgf17 Knockout Mice

A 2008 study reported abnormal social behaviours in mice lacking Fgf17, linking the gene's developmental role to later behavioural phenotypes in the intact animal (PMID 17908176). Findings of this kind describe consequences of genetic deletion and are not statements about what administering the protein would do.

Cerebrospinal Fluid, Oligodendrogenesis and Memory in Aged Mice

The most widely cited recent paper is a 2022 Nature report in which researchers described young cerebrospinal fluid restoring oligodendrogenesis and memory in aged mice, and identified Fgf17 as a mediator of that effect (PMID 35545674). The study was conducted in mice; the verified literature summarised here contains no human trial of FGF17 administration, so the reported outcomes should be read as animal findings rather than clinical results.

Human Genetics: Hypogonadotropic Hypogonadism

FGF17 also appears in human reproductive endocrinology. A 2013 human genetics study reported that mutations in FGF17, along with IL17RD, DUSP6, SPRY4 and FLRT3, were identified in individuals with congenital hypogonadotropic hypogonadism (PMID 23643382). A 2020 report described genotypic and phenotypic spectra of FGFR1, FGF8 and FGF17 mutations in a Chinese cohort with idiopathic hypogonadotropic hypogonadism (PMID 31748124). Both are gene-variant studies: they associate disrupted FGF17 signalling with a clinical phenotype and say nothing about giving the protein.

Outside the Nervous System

Beyond brain and reproductive axis work, FGF17 has been examined in proliferative tissue. The 2004 prostate study reported autocrine growth-factor activity in prostatic epithelium together with upregulation in benign prostatic hyperplasia (PMID 15129425). A 2022 report evaluated FGF10 and FGF17 as prognostic and drug-response markers in acute myeloid leukaemia (PMID 34731724), an example of the term being used as a biomarker rather than an intervention.

As a Laboratory Patterning Reagent

FGF17 is also used as a tool. A 2025 stem-cell study reported patterning effects of FGF17 and cAMP on the generation of dopaminergic progenitors intended for cell-replacement research in Parkinson's disease (PMID 40071608). Here the protein is a culture-medium component used to steer cell identity in vitro.

Reported Research Contexts at a Glance

Adverse Events: What Studies Report

The verified literature covered on this page consists of animal experiments, cultured-cell work, human gene-variant analyses and tissue or dataset associations, not human safety trials, so no tolerability profile for administered FGF17 in people can be summarised from it. The signals that do exist are biological rather than clinical: researchers reported FGF17 upregulation in benign prostatic hyperplasia alongside autocrine growth activity in prostatic epithelium (PMID 15129425), and a separate analysis examined FGF10/FGF17 as prognostic and drug-response markers in acute myeloid leukaemia (PMID 34731724). On the loss-of-function side, human genetics work reported FGF17 mutations in individuals with congenital hypogonadotropic hypogonadism (PMID 23643382). None of these observations describe doses, routes or exposure durations in humans, and none are reported here as evidence of harm or benefit from administration.

Limits of the Current Literature

Three limits recur across the FGF17 record. First, the most striking functional findings — including the CSF and memory work — were generated in mice (PMID 35545674), and mouse brain outcomes do not translate automatically to humans. Second, human FGF17 data are largely genetic: variant studies describe what happens when signalling is disrupted from birth (PMID 31748124), a different question from what exogenous protein does in an adult. Third, the in vitro applications are methodological, using FGF17 as a patterning ingredient in differentiation protocols (PMID 40071608). This page is for educational purposes only and is not medical advice; consult a licensed physician for questions about any medical condition, medication or investigational compound.

References

• Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17 (Nature, 2022)
• Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism (American Journal of Human Genetics, 2013)
• FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia (The Prostate, 2004)
• Fgf17: A regulator of the mid/hind brain boundary in mammals (Differentiation, 2024)
• FGF10/FGF17 as prognostic and drug response markers in acute myeloid leukemia (Current Research in Translational Medicine, 2022)
• Patterning effects of FGF17 and cAMP on generation of dopaminergic progenitors for cell replacement therapy in Parkinson's disease (Stem Cells, 2025)
• Abnormal social behaviors in mice lacking Fgf17 (Genes, Brain, and Behavior, 2008)
• Temporal and spatial gradients of Fgf8 and Fgf17 regulate proliferation and differentiation of midline cerebellar structures (Development, 2000)
• Genotypic and phenotypic spectra of FGFR1, FGF8, and FGF17 mutations in a Chinese cohort with idiopathic hypogonadotropic hypogonadism (Fertility and Sterility, 2020)